ASX 200·· All Ords·· Small Ords·· Resources··
Markets
DXB A$0.22 JDS 52.2

Dimerix Ltd

DXB ·ASX ·Health Care ·Australia

Live price 20 min delayed
A$0.22
Mkt capA$132m
P/En/a
Div yieldn/a
1Y return-58.1%
52-week range$0.16–$0.66
52.2
Jones Dynamic Risk Score
+1.1 since 28 Sep

Scores as at 4 October 2026. Members see this week's.

The Jones Overview

Dimerix (ASX: DXB) is a high-stakes, single-asset biotech company whose survival hinges on a single drug candidate: DMX-200. While marketing materials highlight a proprietary drug-discovery platform, the reality is that almost all capital is funneled into a single global Phase 3 trial for Focal Segmental Glomerulosclerosis (FSGS), a rare and aggressive kidney disease with no current cure. The company keeps the lights on by selling off regional licensing rights for upfront cash to fund these trials, but the bulk of its headline-grabbing "$1.9 billion in milestones" is completely back-ended. Ultimately, DXB is a classic binary biotech play: if the upcoming trial data satisfies the FDA, the stock faces a massive re-rating; if the trial fails, the company has no fallback revenue to support its valuation.

What is DXB's share price doing?

Snapshot

Share price activity
Last price
A$0.22
52 week range
A$0.16 – A$0.66
Position in range
12%
Daily turnover, 10d avg
0.09%
Beta
2.67
Performance
1 week
-2.2%
1 month
-8.3%
3 months
-8.3%
6 months
-46.3%
1 year
-58.1%
3 years
+33.3%
5 years
-21.4%
Since listing
-82.4%
Price return, dividends excluded.
Key fundamentals
P/E
n/a
P/E forward
n/a
PEG
0.72
Price to book
n/a
Dividend yield
0.00%
Return on equity
n/a
Net margin
-427.26%
Debt to equity
n/a
Last full financial year.
Size
Market cap
A$132m
Net debt
-US$11
Revenue
US$5
Total assets
US$41
Shares on issue
600.40m
Size band
Micro cap
JDS rank, global
#24,128 of 52,149
Consensus
Analysts covering
n/a
Consensus rating
Locked
Consensus target
Locked
Implied vs last
Locked
Broker consensus collected by our data vendor. Not our rating.

Latest announcements

11 Oct 2026 Dimerix at Canaccord Drug & Device and Ignite Conferences 04 Oct 2026 First Patient Reaches Four Years in DMX-200 Clinical Program Price sensitive 28 Sep 2026 Notification regarding unquoted securities - DXB 25 Sep 2026 Notification of 2026 Annual General Meeting Date

Company details

Listing
Listed on
Australian Securities Exchange
Ticker
DXB
ISIN
AU000000DXB7
Listing date
4 Feb 1993
Sector
Health Care
Industry
Biotechnology
Index membership
S&P/ASX Emerging Companies Index
Employees
15
Contact and registry
Website
dimerix.com

Insiders

Board and management
Mr Mark Diamond Chair
Dr Nina Webster Managing Director
Mr Hugh Alsop Non-executive Director
Dr Sonia Poli Non-executive Director
Mr Clinton Snow Non-executive Director
Mr Michael Tonroe Company Secretary
Names and titles as published by the exchange.
Director interests and substantial holdings

No director interest or substantial holding notices in the archive for this company yet.

Each notice is the filing itself. The shareholdings and the dealings are stated inside the document, which we link rather than transcribe.

How does Dimerix Ltd score on Alpha360?

The eight tabs below are the Alpha360 factor scores. Built on decades of academic research, Alpha360 grades Dimerix Ltd from 0 to 100 on each dimension against all listed stocks worldwide, so a reading in the 90s is genuinely top-tier rather than a pass mark, and the Jones Dynamic Risk Score blends all eight into a single number. Each tab gives the score, a read of what it looks like in practice, and the numbers beneath it. General information only. Some metrics via Yahoo Finance where our feed is unavailable.

Rank by Jones Dynamic Risk Score
Sector 8 of 34
Country (AU) 679 of 1,794
Global 24,128 of 52,149
Financial history FY21 to FY25, reported in AUD
Pre-2023 members only
Revenue A$5.9m
FY06 FY25
Net income (A$13.3m)
FY06 FY25
  FY25 Jun 2025 FY24 Jun 2024 FY23 Jun 2023 FY22 Jun 2022 FY21 Jun 2021
Profitability
NPAT (A$13.3m) (A$17.1m) (A$13.8m)
NPAT margin -224.1% -2,926.4% -37,517.9%
Revenue A$5.9m A$583.5k A$36.8k
Valuation
Price / book 24.60x 10.29x 13.34x
Market cap A$330.2m A$189.7m A$87.3m
Enterprise value A$262.0m A$167.7m A$85.3m
Shares outstanding 600.40m 557.87m 426.08m
Price / sales 55.84x 325.07x 2,374.19x
EV / sales 44.31x 287.38x 2,318.90x
Growth & efficiency
Revenue growth 913.5% 1,486.0% 1,452.3%
EPS growth 37.3% 11.1% -21.1%
Operating margin -524.3% -2,926.4% -37,517.9%
EBITDA margin -522.2% -2,918.1% -37,365.6%
Asset turnover 0.10 0.02 0.00
Per share
Earnings per share A$-0.02 A$-0.04 A$-0.04
Free cash flow / sh A$-0.02 A$-0.04 A$-0.04
Book value / share A$0.02 A$0.04 A$0.02
Dividend yield 0.0% 0.0% 0.0%
  FY25 Jun 2025 FY24 Jun 2024 FY23 Jun 2023 FY22 Jun 2022 FY21 Jun 2021
Income statement
Revenue A$5.9m A$583.5k A$36.8k
Operating expenses A$36.9m A$17.7m A$13.8m
Research & development A$32.4m A$21.1m A$20.5m
Selling, general & admin A$4.4m A$4.5m A$2.3m
EBITDA (A$30.9m) (A$17.0m) (A$13.7m)
Depreciation & amort A$123.6k A$48.8k A$56.0k
EBIT (A$31.0m) (A$17.1m) (A$13.8m)
Pretax income (A$31.7m) (A$17.1m) (A$13.8m)
Tax (A$18.4m) A$0 A$0
Net income (A$13.3m) (A$17.1m) (A$13.8m)
EPS basic A$-0.02 A$-0.04 A$-0.04
EPS diluted A$-0.02 A$-0.04 A$-0.04
  FY25 Jun 2025 FY24 Jun 2024 FY23 Jun 2023 FY22 Jun 2022 FY21 Jun 2021
Assets
Cash & equivalents A$68.3m A$22.1m A$8.0m
Receivables A$3.6m A$9.5m A$9.6m
Current assets A$72.2m A$31.9m A$17.7m
Property, plant & eq A$117.6k A$162.4k A$27.9k
Total assets A$91.2m A$32.1m A$17.8m
Liabilities & equity
Accounts payable A$14.1m A$305.2k A$5.1m
Short term debt A$0 A$0 A$5.9m
Current liabilities A$22.2m A$3.4m A$11.8m
Long term debt A$0 A$69.5k A$0
Total liabilities A$77.8m A$13.9m A$11.8m
Total debt A$97.5k A$149.7k A$6.0m
Net debt (A$68.2m) (A$22.0m) (A$2.0m)
Total equity A$13.4m A$18.2m A$6.0m
Working capital A$50.0m A$28.6m A$6.0m
Debt to equity 0.73 0.82 99.91
Current ratio 3.26 9.49 1.51
Quick ratio 3.26 9.49 1.51
Retained earnings (A$77.5m) (A$65.2m) (A$49.5m)
  FY25 Jun 2025 FY24 Jun 2024 FY23 Jun 2023 FY22 Jun 2022 FY21 Jun 2021
Cash flow
Operating cash flow A$39.1m (A$7.0m) (A$12.7m)
Change in working cap A$8.3m A$9.1m A$6.1m
Capital expenditure (A$21.0k) (A$15.8k) (A$2.3k)
Free cash flow (A$13.1m) (A$17.0m) (A$13.7m)
Investing cash flow (A$21.0k) (A$15.8k) (A$2.3k)
Debt repaid (A$109.5k) (A$46.7k) (A$51.7k)
Financing cash flow A$7.4m A$21.2m A$11.1m
Net change in cash A$46.1m A$14.1m (A$1.6m)
  FY25 Jun 2025 FY24 Jun 2024 FY23 Jun 2023 FY22 Jun 2022 FY21 Jun 2021
Dividend
Dividend yield 0.0% 0.0% 0.0%
Cover and capacity
Earnings per share A$-0.02 A$-0.04 A$-0.04
Free cash flow / sh A$-0.02 A$-0.04 A$-0.04
Free cash flow (A$13.1m) (A$17.0m) (A$13.7m)
Other capital returns
Shares outstanding 600.40m 557.87m 426.08m
History before 2023 is members only Become a member
The method

Every score on this page comes from Alpha360, the eight-factor model built by Professor Stewart Jones from three decades of published academic research, rescored weekly across more than 50,000 listed companies worldwide.

The research behind Alpha360 → Understand the scores → How Alpha360 works →

Filings & Announcements

Our call

What we rate Dimerix Ltd

Current rating Locked
  • Buy, hold or sell
  • The Alpha360 score and all eight factors
  • Our Top 3 Buys report
  • Free 15-minute walkthrough
Confirm your email for 3 free scorecards of your choice. Members see every company.
Questions

Common questions about DXB

What is Dimerix Ltd's Jones Dynamic Risk Score?
Dimerix Ltd currently scores 52.2 (Average) on the Jones Dynamic Risk Score, ranking 10 of 34 in Biotechnology. The score is recalculated weekly from institutional-grade data.
Is DXB profitable?
Not at the net line on the latest data: Dimerix Ltd reports a net profit margin of -427.3%.
How does DXB compare to its peers?
Ranked by the Jones Dynamic Risk Score, Dimerix Ltd sits 10 of 34 in its Biotechnology peer group. The full peer ranking, with each peer's score, is shown on this page.
Is this personal financial advice?
No. Everything on this page is general information only. It does not take into account your objectives, financial situation or needs, and you should consider whether it is appropriate for you before acting on it. The full General Advice Warning is at the bottom of this page.
What does it cost to see your rating on Dimerix Ltd?
Nothing. Enter your details in the form on this page and our current rating unlocks instantly, along with a free one-on-one walkthrough of the research with our team if you want it. The full written research note is part of membership.
Who builds the scores?
The Jones Dynamic Risk Score and the Alpha360 factor model were built in-house from three decades of academic research. The system scores companies across global markets and is refreshed weekly.
Go deeper

Book a free walkthrough

Fifteen minutes, one on one with our research team: how the scores work, what they say about Dimerix Ltd, and what members get. No cost, no obligation.

Book a walkthrough

The full research note

Members get the complete written research note from the Financial Trends Australia analysts. Information only, not personal financial advice, and no performance is promised.

Become a member

Want our call on another stock?

Tell us the ticker or company name and we will point you to our research, or let you know when its page is live.

General Advice Warning. The information provided by Financial Trends Australia is general in nature and does not take into account your personal objectives, financial situation or needs. It does not constitute personal financial advice. Before acting on any information, you should consider its appropriateness having regard to your own objectives, financial situation and needs, and seek independent professional advice. Where the information relates to a financial product, you should obtain and consider the relevant Product Disclosure Statement (PDS) or offer document before deciding to acquire the product. Past performance is not a reliable indicator of future performance. Financial Trends Australia Pty Ltd (ABN 65 091 191 472) is a Corporate Authorised Representative (AR No. 001320926) of MF & Co. Asset Management Pty Ltd (AFSL No. 520442).